Two studies (9, 10) have reported the advantage in anti-tumor activity of bintrafusp alfa or a similar anti-PD-L1/TGF-βRII molecule over the use of a combination of anti-PD-L1 plus a TGF-β blocking agent. The gene discussed is CD274; the disease is neoplasm.